You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hormone responsive breast cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma

Not yet recruiting
  • Anatomic Stage 0 Breast Cancer AJCC v8
  • +3 more
  • Accelerated Partial Breast Irradiation
  • Duarte, California
    City of Hope Medical Center
Aug 18, 2023

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

Breast Cancer Trial in Worldwide (exemestane, tamoxifen, triptorelin)

Active, not recruiting
Has Results
  • Breast Cancer
  • Burbank, California
  • +227 more
Nov 15, 2022

Breast Cancer Trial in New Brunswick (U-13C-glucose)

Not yet recruiting
  • Breast Cancer
  • New Brunswick, New Jersey
  • +1 more
Feb 16, 2023

Breast Tumors Trial in Beijing, Nanjing, Changsha (Disitamab Vedotin, Toripalimab)

Not yet recruiting
  • Breast Neoplasms
  • Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
  • +2 more
Oct 23, 2023

CDK4/6 Inhibitors in Hormone Receptor-positive Advanced Breast

Not yet recruiting
  • Breast Cancer
  • CDK4/6 inhibitor
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Apr 5, 2023

Breast Cancer Trial (Trastuzumab Deruxtecan)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • (no location specified)
Jul 10, 2023

HR Positive/HER2 Low Expression Metastatic Breast Cancer Trial in Guangzhou, Shantou, Qionghai (Disitamab vedotin, Endocrine

Recruiting
  • HR Positive/HER2 Low Expression Metastatic Breast Cancer
  • Disitamab vedotin
  • Endocrine therapy
  • Guangzhou, Guangdong, China
  • +2 more
Jun 19, 2023

Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian

Not yet recruiting
  • Hormone-receptor-positive Breast Cancer
  • +3 more
  • Aromatase inhibitor
  • +3 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Apr 5, 2023

Hormone Receptor-positive Breast Cancer Trial in Tampa (Cemiplimab, Capecitabine)

Recruiting
  • Hormone Receptor-positive Breast Cancer
  • Tampa, Florida
    Moffitt Cancer Center
Dec 30, 2022

HER2-positive Breast Cancer, Advanced Breast Cancer Trial in Phoenix, Miami, Boston (Prolonged Overnight Fasting,

Not yet recruiting
  • HER2-positive Breast Cancer
  • Advanced Breast Cancer
  • Prolonged Overnight Fasting
  • +2 more
  • Phoenix, Arizona
  • +2 more
Nov 8, 2023

Cancer, Breast, Cancer-related Problem/Condition, Quality of Life Trial in Chicago ("My Guide" (psychoeducation &

Active, not recruiting
  • Cancer, Breast
  • +4 more
  • "My Guide" (psychoeducation & self-management program)
  • Chicago, Illinois
    Northwestern University
Jan 25, 2023

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Trial

Recruiting
  • Anatomic Stage I Breast Cancer AJCC v8
  • +3 more
  • Best Practice
  • +5 more
  • Ames, Iowa
    Mary Greeley Medical Center
Jan 24, 2023

HER2 Negative Breast Cancer Not Immediately Operated Trial (Ribociclib Oral Tablet)

Not yet recruiting
  • HER2 Negative Breast Cancer Not Immediately Operated
  • Ribociclib Oral Tablet
  • (no location specified)
Dec 16, 2022

Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Ocala, Florida
    Ocala Oncology Center PL DBA Florida Cancer Affiliates
Jul 19, 2023

HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

Recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Targeted Therapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Aug 1, 2023

Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Tuebingen, Germany
      Department of Women's Health
    Jun 1, 2023

    Musculoskeletal Syndrome Trial in Minneapolis (CBD-dominant, THC dominant)

    Recruiting
    • Musculoskeletal Syndrome
    • Minneapolis, Minnesota
      University of Minnesota
    Jun 28, 2023

    Breast Tumors Trial in Guangzhou (Trilaciclib, Epirubicin, Cyclophosphamide)

    Not yet recruiting
    • Breast Neoplasms
    • Guangzhou, Gangdong, China
      Sun-yat sen university cancer center
    Jul 30, 2023

    Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma Trial in Canada,

    Active, not recruiting
    Has Results
    • Estrogen Receptor Positive Breast Cancer
    • +7 more
    • Birmingham, Alabama
    • +499 more
    Nov 15, 2022

    Metastatic Breast Cancer Trial in Seoul (Fulvestrant plus AI plus ribociclib, AI plus ribociclib)

    Not yet recruiting
    • Metastatic Breast Cancer
    • Fulvestrant plus AI plus ribociclib
    • AI plus ribociclib
    • Seoul, Korea, Republic of
      Korea university Guro hospital
    Apr 16, 2023

    Brain Metastases, HR+ Metastatic Breast Cancer Trial in Tampa (Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy)

    Recruiting
    • Brain Metastases
    • HR+ Metastatic Breast Cancer
    • Stereotactic Radiosurgery (SRS)
    • +2 more
    • Tampa, Florida
      Moffitt Cancer Center
    Nov 1, 2022

    Breast Cancer Trial in Tianjin (Dalpiciclib, Pyrotinib, Fulvestrant)

    Not yet recruiting
    • Breast Cancer
    • Tianjin, China
      Tianjin Cancer Hospital
    Mar 28, 2023

    Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Inflammatory Carcinoma Trial in

    Active, not recruiting
    • Anatomic Stage IIIB Breast Cancer AJCC v8
    • +4 more
    • Pembrolizumab
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 30, 2022

    Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Oct 10, 2022